Versartis

^{Priced, Nasdaq: VSAR}

Biotech developing long-acting treatments for growth hormone deficiency.

Industry: Health Care

First Day Return: +49.4%

VSAR

Biotech developing long-acting treatments for growth hormone deficiency.

IPO News for Versartis

Growth hormone biotech Ascendis Pharma files for a $86 million IPO 12/18/14
US IPO Recap: Year's largest biotech IPO Versartis jumps 49% amid tech-biotech frenzy 03/24/14
Versartis prices IPO at $21, the high end of the revised range 03/21/14

IPO Data
IPO Date	03/20/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$126
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.versartis.com
Headquarters	Redwood City, CA, United States
Founded	2008
Employees at IPO	14

IPO News for Versartis

Versartis (VSAR) Performance